vs

Side-by-side financial comparison of CABOT CORP (CBT) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

CABOT CORP is the larger business by last-quarter revenue ($849.0M vs $568.5M, roughly 1.5× Real Brokerage Inc). CABOT CORP runs the higher net margin — 8.6% vs -0.1%, a 8.7% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs -11.1%). CABOT CORP produced more free cash flow last quarter ($57.0M vs $8.4M).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

CBT vs REAX — Head-to-Head

Bigger by revenue
CBT
CBT
1.5× larger
CBT
$849.0M
$568.5M
REAX
Growing faster (revenue YoY)
REAX
REAX
+63.7% gap
REAX
52.6%
-11.1%
CBT
Higher net margin
CBT
CBT
8.7% more per $
CBT
8.6%
-0.1%
REAX
More free cash flow
CBT
CBT
$48.6M more FCF
CBT
$57.0M
$8.4M
REAX

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
CBT
CBT
REAX
REAX
Revenue
$849.0M
$568.5M
Net Profit
$73.0M
$-447.0K
Gross Margin
24.9%
7.9%
Operating Margin
15.2%
-0.1%
Net Margin
8.6%
-0.1%
Revenue YoY
-11.1%
52.6%
Net Profit YoY
-21.5%
82.7%
EPS (diluted)
$1.37
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
REAX
REAX
Q4 25
$849.0M
Q3 25
$899.0M
$568.5M
Q2 25
$923.0M
$540.7M
Q1 25
$936.0M
$354.0M
Q4 24
$955.0M
Q3 24
$1.0B
$372.5M
Q2 24
$1.0B
Q1 24
$1.0B
$200.7M
Net Profit
CBT
CBT
REAX
REAX
Q4 25
$73.0M
Q3 25
$43.0M
$-447.0K
Q2 25
$101.0M
$1.5M
Q1 25
$94.0M
$-5.0M
Q4 24
$93.0M
Q3 24
$137.0M
$-2.6M
Q2 24
$109.0M
Q1 24
$84.0M
$-16.1M
Gross Margin
CBT
CBT
REAX
REAX
Q4 25
24.9%
Q3 25
24.5%
7.9%
Q2 25
26.4%
8.9%
Q1 25
25.7%
9.6%
Q4 24
24.6%
Q3 24
24.0%
8.6%
Q2 24
25.2%
Q1 24
24.1%
10.3%
Operating Margin
CBT
CBT
REAX
REAX
Q4 25
15.2%
Q3 25
15.2%
-0.1%
Q2 25
18.1%
0.3%
Q1 25
17.3%
-1.5%
Q4 24
16.2%
Q3 24
15.0%
-0.7%
Q2 24
16.9%
Q1 24
15.3%
-7.8%
Net Margin
CBT
CBT
REAX
REAX
Q4 25
8.6%
Q3 25
4.8%
-0.1%
Q2 25
10.9%
0.3%
Q1 25
10.0%
-1.4%
Q4 24
9.7%
Q3 24
13.7%
-0.7%
Q2 24
10.7%
Q1 24
8.2%
-8.0%
EPS (diluted)
CBT
CBT
REAX
REAX
Q4 25
$1.37
Q3 25
$0.80
$0.00
Q2 25
$1.86
$0.01
Q1 25
$1.69
$-0.02
Q4 24
$1.67
Q3 24
$2.41
$-0.01
Q2 24
$1.94
Q1 24
$1.49
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$230.0M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.6B
$53.6M
Total Assets
$3.8B
$145.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
REAX
REAX
Q4 25
$230.0M
Q3 25
$258.0M
$38.7M
Q2 25
$239.0M
$49.7M
Q1 25
$213.0M
$24.7M
Q4 24
$183.0M
Q3 24
$223.0M
$22.6M
Q2 24
$197.0M
Q1 24
$206.0M
$20.1M
Total Debt
CBT
CBT
REAX
REAX
Q4 25
Q3 25
$1.1B
Q2 25
Q1 25
Q4 24
Q3 24
$1.1B
Q2 24
Q1 24
Stockholders' Equity
CBT
CBT
REAX
REAX
Q4 25
$1.6B
Q3 25
$1.6B
$53.6M
Q2 25
$1.5B
$49.2M
Q1 25
$1.4B
$32.8M
Q4 24
$1.4B
Q3 24
$1.4B
$29.8M
Q2 24
$1.3B
Q1 24
$1.4B
$25.6M
Total Assets
CBT
CBT
REAX
REAX
Q4 25
$3.8B
Q3 25
$3.8B
$145.2M
Q2 25
$3.8B
$149.4M
Q1 25
$3.8B
$100.5M
Q4 24
$3.6B
Q3 24
$3.7B
$102.5M
Q2 24
$3.6B
Q1 24
$3.6B
Debt / Equity
CBT
CBT
REAX
REAX
Q4 25
Q3 25
0.70×
Q2 25
Q1 25
Q4 24
Q3 24
0.75×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
REAX
REAX
Operating Cash FlowLast quarter
$126.0M
$8.8M
Free Cash FlowOCF − Capex
$57.0M
$8.4M
FCF MarginFCF / Revenue
6.7%
1.5%
Capex IntensityCapex / Revenue
8.1%
0.1%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
REAX
REAX
Q4 25
$126.0M
Q3 25
$219.0M
$8.8M
Q2 25
$249.0M
$41.0M
Q1 25
$73.0M
$15.9M
Q4 24
$124.0M
Q3 24
$204.0M
$7.2M
Q2 24
$207.0M
Q1 24
$176.0M
$21.5M
Free Cash Flow
CBT
CBT
REAX
REAX
Q4 25
$57.0M
Q3 25
$155.0M
$8.4M
Q2 25
$188.0M
$40.8M
Q1 25
$1.0M
$15.7M
Q4 24
$47.0M
Q3 24
$112.0M
$6.8M
Q2 24
$155.0M
Q1 24
$133.0M
$21.4M
FCF Margin
CBT
CBT
REAX
REAX
Q4 25
6.7%
Q3 25
17.2%
1.5%
Q2 25
20.4%
7.5%
Q1 25
0.1%
4.4%
Q4 24
4.9%
Q3 24
11.2%
1.8%
Q2 24
15.3%
Q1 24
13.1%
10.7%
Capex Intensity
CBT
CBT
REAX
REAX
Q4 25
8.1%
Q3 25
7.1%
0.1%
Q2 25
6.6%
0.0%
Q1 25
7.7%
0.1%
Q4 24
8.1%
Q3 24
9.2%
0.1%
Q2 24
5.1%
Q1 24
4.2%
0.0%
Cash Conversion
CBT
CBT
REAX
REAX
Q4 25
1.73×
Q3 25
5.09×
Q2 25
2.47×
27.13×
Q1 25
0.78×
Q4 24
1.33×
Q3 24
1.49×
Q2 24
1.90×
Q1 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

REAX
REAX

Segment breakdown not available.

Related Comparisons